For many COPD patients, consider twice-daily BROVANA® (arformoterol tartrate)
You can review various COPD patient types to see how nebulized therapy with BROVANA® (arformoterol tartrate) Inhalation Solution may benefit your COPD patients. There is also an overview of the GOLD guidelines and their recommendations for treating moderate to very severe COPD with long-acting bronchodilators.1
Click below to review 4 COPD patient types:
Have a low peak inspiratory flow rate (PIFR)
As with other inhaled beta2-agonists, BROVANA® (arformoterol tartrate) Inhalation Solution can produce paradoxical bronchospasm that may be life-threatening.
Using a nebulized, short-acting bronchodilator ≥4 times daily
BROVANA® (arformoterol tartrate) Inhalation Solution is not indicated for the treatment of acute episodes of bronchospasm, ie, rescue therapy, and does not replace fast-acting rescue inhalers.
Patients who have been taking inhaled short-acting beta2-agonists on a regular basis should be instructed to discontinue their regular use and to use them only for symptomatic relief for acute respiratory symptoms.
Have coordination or dexterity limitations
Could benefit from adding a long-acting bronchodilator to their current tiotropium therapy
BROVANA® (arformoterol tartrate) Inhalation Solution should not be used in conjunction with other inhaled, long-acting beta2-agonists. BROVANA should not be used with other medications containing long-acting beta2-agonists.
Not actual COPD patients